Chapter 674 Global shock!
Like the most important one, DDR1.
Its discovery is not only a therapeutic target, but also an important marker for evaluating the prognosis of metastatic liver cancer!
If you choose to sell it, the discovery of this target alone may be able to be sold to many pharmaceutical companies for hundreds of millions of yuan...
Other targets are at least 100 million.
Xu Qiu only spent 600 million this month, but the liver cancer target he developed can be sold for at least a billion. This profit margin is enough to make any industry envious!
However, it is impossible for Xu Qiu to sell off this wealth of knowledge...
The sales target is several hundred million yuan, a one-time deal.
And if a corresponding targeted drug is developed for one of the targets, the profits will be a huge market exceeding 10 billion yuan every year!
This can be seen from the fact that Huining fought tooth and nail to keep his liver in peace.
Moreover, a liver full of defects can still make a lot of money in countries such as Daxia. Last year, Huining sold more than 100 billion berries globally and earned 30 billion, including 250 million. From liver tranquility…
You must know that this is the second largest pharmaceutical company in the world. It owns hundreds of drugs. It is already a myth that one product can earn them nearly 1% of the total profit!
These are only drugs that are circulated privately in some countries...
If it has no defects and is truly marketed globally, the profits it will bring are unimaginable!
"Focus on CRM17 and conduct in-depth research along the new mechanism of angiogenesis in liver cancer." Xu Qiu gave the focus of the next step of research and development.
Mo Wan's face was filled with astonishment... She originally thought that DDR1 was the key point, but she didn't expect that Xu Qiu would give such great importance to this new mechanism discovered by her!
When the order was conveyed to the Drug Research and Development Institute, the three academicians, Han Chang and others were also shocked.
They also found it incredible.
From all aspects, DDR1 is based on the discovered pathogenic mechanism. It ranks first among the eleven targets in terms of success rate, practicality, potential, etc.
However, Xu Qiu still chose DDR1 in the end.
"Xu Qiu has great ambitions. He wants to use this new mechanism to develop an original drug that is completely his..." An academician guessed Xu Qiu's purpose.
Another academician nodded in alarm: "If it is other targets, they are basically under the mechanism of liver cancer that has been discovered long ago, and there are similar alternative drugs. But if it is a new mechanism, it is equivalent to starting a new track. , even the well-established sorafenib, canvatinib, etc. cannot compete with it!”
But the risks are very high.
There is indeed a chance to avoid competition with established miracle drugs by starting a new one. After all, even sorafenib has a clinical effectiveness of only 10% to 30%. When targeting the same mechanism, no matter whether it is a clinician, Patients, regardless of price, will choose sorafenib, which is more suitable.
But if it is a brand-new treatment mechanism, it may bring a huge shock to the medical community and clinical practice...
However, the hardships involved are unpredictable. The difficulty and cost of research and development are at least several times that of other targets. Is 5 billion really enough? Can it really be completed in five months?
…
…
When the research and development of new liver drugs was in full swing, the news of recruiting talents and seconding equipment from various places in Daxia also alarmed countless people.
Little Japan, Eisai Co., Ltd.
Canavatinib, one of the first-line treatments for advanced liver cancer, was developed by Eisai Co., Ltd. It is especially suitable for the treatment of unresectable hepatocellular carcinoma that has not received systemic treatment before. The price is sorafenib. Twice that, even with medical insurance, the price of each pill is around 560 yuan.
"This person named Xu Qiu... actually wants to develop liver drugs?" Inside the Eisai Drug Research and Development Institute, a sneer flashed in the eyes of the chief researcher.
Liver cancer drug research and development is fraught with difficulties.
Their company's canamvatinib is a product that has been "sharpened for ten years". After painstaking research and dormancy for more than ten years, it has achieved an astonishing objective response rate of 43.8%, and it has become the first choice for liver cancer patients. One of the most important therapeutic drugs.
And it is rumored that Xu Qiu actually plans to spend 5 billion to complete research and development within five months...
It’s not even a fraction of the price of Canavatinib.
This is just a joke!
A man with small eyes sneered: "Xu Qiu is driven crazy by Gan An Ning."
Another person said: "He has created too many miracles in other fields, so he thinks drug research and development does not require brainpower!"
"We at Eisai have thousands of employees, and it took us ten years to develop cavatinib. If this guy from Daxia can really succeed in developing it, I will go to Linhai in person to apologize to him!"
"He seems to be a candidate for the Daxia World Series. No wonder it takes five months to complete. He will go to the World Series in five months..."
"It's ridiculous. If we had good dealings with the supervision team, started research and development in advance, and waited for the world competition to enter the liver cancer drug as an entry, Xu Qiu might really have been ranked in the top ten, or even the top five, but the result was so stupid!"
"Just wait, he may soon know that the difficulty of drug development cannot be compared with improved surgery!"
The top management of Eisai Co., Ltd. all sneered and were ready to watch the excitement.
…
Huining Pharmaceutical Headquarters.
As the second largest pharmaceutical company in the world, Huining has many products that are very important in the world, such as penicillin, oxytetracycline, sildenafil, etc., all of which are super single products from Huining...
Liver Anning was originally expected to become the next new favorite. However, after it suffered setbacks in the clinical trial stage and failed to pass the review of China's State Food and Drug Administration, it could only turn to other countries such as China.
But despite this, Gananning's ability to attract money is still beyond everyone's expectation at Huining... Of the 30 billion in profit last year, 250 million came from this product, which really shocked everyone.
However, just when Gan Anning was planning to open up a large market in Daxia, Xu Qiu came out and took Baiyun Province away from Gan Anning's market territory. A few provinces such as Yudi also secretly resisted Gan Anning...
Within a few months, many provinces were wiped out from the market landscape.
But Huining never paid attention to it... Gan An Ning's low price and efficacy allowed him to sell well despite the ban. No matter how Xu Qiu and Bai Yun Sheng escaped, at most Gan An Ning would switch from selling openly to selling secretly. circulated.
However, when Xu Qiu settled in Baiyun Pharmaceutical Factory and started research and development of new liver cancer drugs with great fanfare, Huining finally panicked!
But it didn't last long.
When they learned that Xu Qiu planned to develop a new drug within five months and five billion, they were relieved again.
Let alone Huining, even if it is the world's largest pharmaceutical company, it is almost impossible to complete all this within half a year regardless of the cost, regardless of the cost!
Just experimenting with thousands of compound combinations could take years!
